Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
HORIZON-Breast06
SHR-A1811 Versus Investigator's Chemotherapy in Recurrent/Metastatic Breast Cancer Clinical Trial
- NCT05814354 ↗
- Active, not recruiting
- Jiangsu HengRui Medicine Co., Ltd.
- Deep
We haven't built an HCP commentary report on HORIZON-Breast06 (SHR-A1811 and Capecitabine/Eribulin/Gemcitabine/Paclitaxel/Nab-paclitaxel in Breast Cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on HORIZON-Breast06 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 35 | |
| YouTube | 1 | |
| Podcasts | 1 | |
| Bluesky threads | 1 | |
| X videos | 1 |
The trial
ClinicalTrials.gov- Official title
- A Randomized, Open, Parallel-controlled, Multicenter Phase III Trial of SHR-A1811 Versus Investigator Chemotherapy in HER2-low Expressing Recurrent/Metastatic Breast Cancer
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Breast Cancer
- Interventions
- SHR-A1811; Capecitabine/Eribulin/Gemcitabine/Paclitaxel/Nab-paclitaxel
- Arms
- SHR-A1811 · Experimental
- Physician's Choice · Active comparator
- Enrollment
- 551
- Primary outcomes
- Progression-free Survival (PFS) Based on Blind Independent Video Review Committee (BIRC)
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Start
- Jun 30, 2023
- Primary completion
- Mar 20, 2026
- Results posted
- No
- Registry record
- NCT05814354 · updated Aug 6, 2026
Publications
linked from the registry- Fan Y, Liu Y, Wang Y, Ouyang Q, Zhang Q, Cui J, Li J, Ding Q, Wu X, Wang X, Tong Z, Zeng Y, Wang W, Yan M, Wang Y, Liu X, Li K, Sun Z, Yuan C, Wang T, Xie W, Yao J, Zhou S, Hou J, Ouyang Z, Li Y, Cui S, Zhang X, Zhu X, Xu B. Trastuzumab Rezetecan in ERBB2-Low Advanced Breast Cancer: The HORIZON-Breast06 Randomized Clinical Trial. JAMA. 2026 Oct 23:e2621372. doi: 10.1001/jama.2026.21372. Online ahead of print. PubMed 42925007